MarketCap
Facebook
X
Telegram
Novavax ROA Ratio | NVAX
Annual ROA Ratio Novavax
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.42 | -12.02 | -30.32 | -29.13 | -67.67 | -26.43 | -76.72 | -88.83 | -60.75 | -71.0 | -40.65 | -30.05 | -22.03 | -27.85 | -29.09 | -47.71 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.42 | -88.83 | -38.93 |
Quarterly ROA Ratio Novavax
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.68 | 30.02 | 23.85 | 49.93 | 34.07 | -6.05 | -2.6 | -14.57 | -23.5 | -23.5 | -30.94 | -42.51 | -38.77 | -19.72 | -32.29 | -37.67 | -26.74 | -33.92 | -46.39 | -34.93 | -23.75 | -15.21 | -33.61 | -31.58 | -53.37 | -76.72 | -82.04 | -93.04 | -91.53 | -88.83 | -81.92 | -75.23 | -68.54 | -60.75 | -58.43 | -60.48 | -65.91 | -71.0 | -76.93 | -68.71 | -53.93 | -40.65 | -31.67 | -30.24 | -31.36 | -30.05 | -24.6 | -23.96 | -22.86 | -22.11 | -23.98 | -24.53 | -24.94 | -27.85 | -25.57 | -23.34 | -25.06 | -29.08 | -4.82 | -7.5 | -11.19 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.93 | -93.04 | -34.57 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
41.33 | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Allakos
ALLK
|
-119.89 | - | - | $ 28.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
15640.17 | $ 1.88 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
-13.62 | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-48.42 | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
-177.72 | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
4.59 | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
BioNTech SE
BNTX
|
-5.17 | $ 98.52 | 0.24 % | $ 23.8 B |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M |  Britain |
 |
Genocea Biosciences
GNCA
|
-59.31 | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
5.95 | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
-29.24 | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
-29.75 | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Amryt Pharma plc
AMYT
|
0.12 | - | - | $ 621 M | Britain |
 |
Cerus Corporation
CERS
|
-7.04 | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
-39.47 | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-106.53 | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
Cellectar Biosciences
CLRB
|
-145.48 | $ 1.8 | 0.72 % | $ 4.69 M | USA |
 |
AbbVie
ABBV
|
1.36 | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
-631.8 | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
-90.93 | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-32.42 | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
3.8 | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
11.91 | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
Фармсинтез
LIFE
|
-25.57 | - | - | - |  Russia |
 |
IGM Biosciences
IGMS
|
-73.69 | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
-64.89 | - | - | $ 123 M | USA |
 |
Cardiff Oncology
CRDF
|
-0.07 | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-46.69 | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
-32.46 | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
-37.97 | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
19.74 | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.31 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
|
Champions Oncology
CSBR
|
-4.35 | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
-60.54 | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-21.51 | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
-63.02 | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
-90.25 | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-35.41 | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
-55.1 | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
-41.26 | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
-22.5 | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
-53.39 | $ 7.94 | 1.4 % | $ 373 M | USA |